Tempus ai today
As of 9/9/2025 203: 58
- 52-week range
- $ 22.89
▼
$ 91,45
- Value is valuable
- $ 61.50
Tempus you have NASDAQ: TEM An interesting story of AI, which controls the platform and library for Diagnosis and opening of drugsThe platform helps doctors, providing personalized assistance in the conditions of the treatment of diseases and pharmaceutical companies, such as Astrazeneca NASDAQ: AZNWith achievements in medicine is impossible without computerized help. The results of the company are evidence of its usefulness, growing on High two -digit pace in 2025And it can be a catalyst for a significant and stable rally.
The results of Q1 2025 show losses, but also improve the quality of operation and cash flow. Among critical details – Forecast of the financial director for adjusted EBITDA profit By the end of the year. The prognosis of profit is cool, about 5 million dollarsBut this is the first drop in the flow of profit to help Joint -stock growth in value In the long run.
Institutions against short sellers: actions on the sales side are moving into the volatility in Tempus AI shares
Short sales and dilution are one of the factors that give pressure on Tempus AI reserves in 2025. Short interest Reported in April, was high in 26% And they grow compared to the previous month, creating a counter wind for the market. Short interest can remain high from the lack of profit in 2025, but there is a risk for short sellers and the opportunity for investors. There is a company take ahead and increase the leadershipAnd institutional activity is growing. Institutional possessions Stay small approximately 25% From the float, but their activity is a passing substance for the market, which can exert pressure on the short side for the coating.
TEMPUS AI promotion forecast today
$ 61.50
0.26% growthModerate purchase
Based on 13 analysts ratings
| The current price | $ 61.34 |
|---|---|
| High forecast | $ 74.00 |
| Average forecast | $ 61.50 |
| Low forecast | $ 48.00 |
TEMPUS AI shares forecast details
A Q1 results were good. The company reported 75.4% in annual calculus height And Expects acceleration this year. The force was due to profit in both segments, with The main segment of genomics Grow 89% to 194 million dollars. USA, or approximately 76% of income.
A Data service segment It was also strong, but grew by 43%. A more significant factor in this star report is that gross profit increased at a 100% pace, which helps to reduce operating losses by more than 50%.
A The company raised its leadership From a combination of strengths Q1 and a new deal with Astrazeneca. The deal will be Partner Tempus with Astrazeneca and Pathos To build The world’s largest multimodal oncological fundworth 200 million dollars over the next three years, with the exception of other income that he can bring.
Pure result is that management Expects an increase in revenue for a year by 80%At 500 basic points from the first quarter, and acceleration is expected to the nearest quarters. The Astrazeneca transaction is also significant for long -term prospects. Tempus has already announced the interests of other pharmaceutical giants and in the near future may announce additional transactions.
Analysts can provide a catalyst for Tempus AI shares in 2025
A Analytics data tracked by Marketbeat TEMPUS AI shares survey, including an increase in the coating, strengthening Moderate purchase ratingAnd Increasing price goalsThey see the field that this action has grown by at least 10% compared to price points in early May and can catalyze the rally now, when the leadership was updated. A significant series of positive changes, including modernization and increasing the price target price price, will improve investors’ trust and leading capital to enter the market.
A Price action in early May It suggests that capital began to return to the market. Not only did the price effect bounced off new minimums, but also checked and confirmed support in the cluster of the moveting medium. These include critical 30 and 150-day EMA, representing short-term traders and long-term investors, and they probably Launching Point for RallyThe field assuming that the market follows this signal, it can increase to $ 70 by the beginning of summerField
Before considering Tempus ai, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before a wider market is won … and Tempus AI was not on the list.
While Tempus AI currently has a moderate purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Need to place your plan 401k or Roth Ira? Use these investigation strategies that have time -tested time to increase the monthly pension income that generates your shares portfolio.
Get this free report